WebAn agency of the European Union Section 5.1: Pharmacodynamic properties Rev. 1 SmPC training presentation Note: for full information refer to the European Commission’s … WebAbstract. Objective: A post-authorisation commitment to the Spanish Regulatory Agency was made to evaluate the safety of the tetanus, diphtheria and acellular pertussis vaccine …

REPEVAX - Summary of Product Characteristics (SmPC) - (emc)

WebSmPC or Summary of Product Characteristics is a legal document which is a part of the marketing authorization of every medicine. The document acts as a basis of information on the use of medicines for healthcare professionals. The information included in the SmPC is updated regularly as per the emergence of the latest information. Web240 mg (two 120 mg tablets) once daily. Adverse reaction. Severity a. Dose modification. Hepatotoxicity. Grade 2 AST or ALT with symptoms. or. Grade ≥ 3 AST or ALT. • Stop treatment until recovered to ≤ grade 1 or to baseline grade. size of drainfield

London, 20 November 2008 - Public Health

WebSmPC requires mandatory information in several sections of the SmPC e.g. sections 4.2, 4.4, 4.5, 5.1, to address the appropriate use in children Elderly population •Similarly, … WebSmPC Datum van herziening van de tekst: Laatste gedeeltelijke wijziging betreft de rubrieken 4.2 en 5.1: 3 juni 2024 . ... Wat is TRIAXIS en waarvoor wordt dit middel gebruikt* Triaxis (Tdap) is een vaccin. Vaccins worden gebruikt om te beschermen tegen infectieziekten. WebSep 23, 2024 · Triaxis (Tdap) is a vaccine. Vaccines are used to protect against infectious diseases. They work by causing the body to produce its protection against the bacteria that cause these diseases. This vaccine is used to boost protection against diphtheria, tetanus, and pertussis in children from 4 years of age, adolescents, and adults, after a ... sizeof double 是什么表达式